Ventus Therapeutics
Waltham, US · Founded 2019 · Delaware corporation · 53 employees on LinkedIn · 5 known investors
Ventus discovers and develops small-molecule medicines using its proprietary ReSOLVE platform, focused on structure-based drug discovery. The company has advanced lead programs in Parkinson's disease and lupus through Phase 2 clinical trials.
Founders & leadership
Ventus Therapeutics was founded in 2019 by Judith Lieberman.
JL
Judith LiebermanCo-Founder, MD, PhD
DK
Daniel KoerwerExecutive
MC
Michael CrackowerExecutive
ZM
Zachary McNealyExecutive
Board
JR
Josh ResnickBoard director
JD
BB
MB
SJ
Steven JamesBoard director
Investors · 5
Reported raises · per SEC filings
Form D private placements$186.8M disclosed across 3 rounds · 2019–2022
▶$70MraisedFeb 2022 · 13 investors · BiotechnologyRule 506(b)
▶$70MraisedFeb 2022 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven JamesDirector
- Daniel KoerwerExecutive Officer
- Josh ResnickDirector
- Markus WarmuthDirector
- Michael CrackowerExecutive Officer
- Jane Pritchett HendersonDirector
- Jerel DavisDirector
- Marcelo BigalExecutive Officer, Director
- Dolca ThomasDirector
- Brendan Bulik-SullivanDirector
- John CassidyDirector
- Zachary McNealyExecutive Officer
- Offering amount
- $140M
- Amount sold
- $70M
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$100MraisedApr 2021 · 17 investors · BiotechnologyRule 506(b)
▶$100MraisedApr 2021 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel KoerwerExecutive Officer
- Josh ResnickDirector
- Jerel DavisDirector
- Steven JamesDirector
- Brendan Bulik-SullivanDirector
- Michael CrackowerExecutive Officer
- Zachary McNealyExecutive Officer
- Marcelo BigalExecutive Officer, Director
- Offering amount
- $100M
- Amount sold
- $100M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$16.8MraisedMay 2020 · 4 investors · BiotechnologyRule 506(b)
▶$16.8MraisedMay 2020 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jerel DavisDirector
- Daniel KoerwerExecutive Officer
- Hao WuDirector
- Zachary McNealyExecutive Officer
- Brendan Bulik-SullivanDirector
- Marcelo BigalExecutive Officer, Director
- Offering amount
- $60.1M
- Amount sold
- $16.8M
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Ventus Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Ventus Therapeutics do?
- Ventus discovers and develops small-molecule medicines using its proprietary ReSOLVE platform, focused on structure-based drug discovery. The company has advanced lead programs in Parkinson's disease and lupus through Phase 2 clinical trials.
- Who founded Ventus Therapeutics?
- Ventus Therapeutics was founded by Judith Lieberman in 2019.
- Who are Ventus Therapeutics's investors?
- Ventus Therapeutics's investors include Andreessen Horowitz, GV (Google Ventures), RA Capital, SoftBank Vision Fund, Versant Ventures.
- How much funding has Ventus Therapeutics raised?
- Ventus Therapeutics has disclosed $186.8M raised across 3 rounds.
- Where is Ventus Therapeutics headquartered?
- Ventus Therapeutics is headquartered in Waltham, US.